Adc Therapeutics SA (NYSE:ADCT) has a beta value of -54.37% and has seen 563.71 shares traded in the last trading session. The company, currently valued at $274.72M, closed the last trade at $3.03 per share which meant it lost -$5.17 on the day or 2.77% during that session. The ADCT stock price is -36.3% off its 52-week high price of $4.13 and 65.35% above the 52-week low of $1.05. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.84 million shares traded. The 3-month trading volume is 2.35 shares.
The consensus among analysts is that Adc Therapeutics SA (ADCT) is Buy stock at the moment, with a recommendation rating of 47.51. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 7 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
Adc Therapeutics SA (NYSE:ADCT) trade information
Sporting 2.77% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ADCT stock price touched $3.03 or saw a rise of 23.68%. Year-to-date, Adc Therapeutics SA shares have moved -1.77%, while the 5-day performance has seen it change -24.52%. Over the past 30 days, the shares of Adc Therapeutics SA (NYSE:ADCT) have changed 28.84%. Short interest in the company has seen 4.27 million shares shorted with days to cover at 6.56.
Wall Street analysts have a consensus price target for the stock at $8, which means that the shares’ value could jump 62.13% from current levels. The projected low price target is $7.0 while the price target rests at a high of $13.0. In that case, then, we find that the current price level is -329.04% off the targeted high while a plunge would see the stock gain -131.02% from current levels.
Adc Therapeutics SA (ADCT) estimates and forecasts
The company’s shares have gained 38.50% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 18.47% 1.38% over the past 5 years. Earnings growth for 2025 is a modest 7.41% while over the next 5 years, the company’s earnings are expected to increase by 16.36%.
ADCT Dividends
Adc Therapeutics SA is expected to release its next earnings report on 2025-May-14 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
Insiders own 21.59% of the company shares, while shares held by institutions stand at 67.58% with a share float percentage of 86.19%. Investors are also buoyed by the number of investors in a company, with Adc Therapeutics SA having a total of 115.0 institutions that hold shares in the company. The top two institutional holders are REDMILE GROUP, LLC with over 15.27 million shares worth more than $48.25 million. As of 2024-06-30, REDMILE GROUP, LLC held 15.9568% of shares outstanding.
The other major institutional holder is PROSIGHT MANAGEMENT, LP, with the holding of over 9.57 million shares as of 2024-06-30. The firm’s total holdings are worth over $30.24 million and represent 10.0009% of shares outstanding.
